> "We can only cure what we can understand first"
>
> Otto Warburg

Introduction
============

Modern medicine faces an almost total lack of success both in the prevention and treatment of human neurodegenerative diseases (HNDDs), like Alzheimer's disease (AD), multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), Hungtington's disease (HD), retinitis pigmentosa (RP), and others. Symptomatic treatments are available for other processes, such as Parkinson's disease (PD). The main problem seems to lie in the fact that it has not been so far possible to prevent, stop or reverse the premature and spontaneous process of progressive cell death or programmed cell death (PCD) via apoptosis or related mechanisms in HNDDs (paraptosis, autophagy, etc) ([@b59-ndt-4-1073]). New conceptual approaches appear most necessary in order to discover novel therapies for the prevention and treatment of these processes ([@b125-ndt-4-1073]; [@b71-ndt-4-1073]; [@b18-ndt-4-1073]).

Attempts to advance an integral and unifying hypothesis on the etiopathogenesis of HNDDs have been proposed for decades. This has mainly focused on the lack in growth factor (GF) stimulation, mainly on deficiencies in nerve growth factor (NGF) ([@b10-ndt-4-1073]; [@b61-ndt-4-1073]; [@b118-ndt-4-1073]). PCD in HNDDs, either apoptosis-mediated or not, can be induced either by: A) Depletion, spontaneous or induced, of different GFs, either from neural origin or otherwise (trophic factor withdrawal, or TFW) ([@b102-ndt-4-1073]; [@b68-ndt-4-1073]; [@b133-ndt-4-1073]; [@b108-ndt-4-1073]), and/or B) The activation or overexpression of mechanisms that stimulate PCD (ie, caspases, etc.), which can also be secondary to TFW-mediated mechanisms ([@b125-ndt-4-1073]; [@b133-ndt-4-1073]; Liu et al 2004; [@b73-ndt-4-1073];Riedl et al 2005). While acting upon mechanism *B* is to a great deal still controversial, mechanism *A* can be to a certain extent counteracted through the therapeutic utilization of a wide array of trophic and/or human GFs in order to control and/or even suppress pathological cell death programs (PCDP). The utilization of GFs, besides preventing cell death, is used to stimulate cell growth and proliferation in a wide array of clinical settings in modern clinical practice ([Table 1](#t1-ndt-4-1073){ref-type="table"}) (Varon 1981; [@b13-ndt-4-1073]; [@b68-ndt-4-1073]; [@b133-ndt-4-1073]; [@b2-ndt-4-1073], [@b6-ndt-4-1073]; [@b3-ndt-4-1073]). Recently, several plasma signaling proteins have been found to be significantly deficient even in preclinical and asymptomatic stages of AD, revealing a decrease in the circulation of different hematopoiesis-dependent GFs, like platelet-derived growth factor (PDGF), transforming growth factor-1 (TGF-1), epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), hepatocyte growth factor (HGF), etc., in this disease ([@b101-ndt-4-1073]). Since several of them, like PDGF, TGF-1, EGF, VEGF, bFGF, HGF, bone morphogenetic protein-2 (BMP-2), -4, -6, connective tissue growth factor (CTGF), etc. ([Table 2](#t2-ndt-4-1073){ref-type="table"}) ([@b2-ndt-4-1073]; [@b70-ndt-4-1073]), are contained in high concentrations in young functional platelets and/or leukocytes, it becomes surprising that while highly sophisticated methods are being investigated to induce and increase the activity of a cohort of growth factors, either from neural origin or not, in different models of HNDDs ([@b126-ndt-4-1073]; [@b141-ndt-4-1073]; [@b143-ndt-4-1073]), at least to our knowledge no previous mention has been made on the possibility of using young and healthy platelets and, perhaps to a lesser degree, leukocyte transfusions, their most widespread natural source, in the treatment of certain HNDDs. The apparent lack of specificity in the stimulation of tissue regeneration by a cohort of several trophic factors and other cytokines contained in young and healthy platelets ([Table 2](#t2-ndt-4-1073){ref-type="table"}) ([@b2-ndt-4-1073], [@b3-ndt-4-1073], [@b4-ndt-4-1073], [@b6-ndt-4-1073], [@b7-ndt-4-1073]) led us to introduce the concept of a general "trophic factor withdrawal syndrome" in recent publications of our group ([@b6-ndt-4-1073]; [@b59-ndt-4-1073], [@b60-ndt-4-1073]). Finally, since epigenetic and genetic factors can primarily influence the susceptibility to neurodegeneration, the implementation of personalized treatments based on pharmacogenetic principles are also acquiring an increasing importance in order to optimize the so far limited therapeutic resources nowadays available in these complex neurodegenerative disorders ([@b20-ndt-4-1073]; [@b21-ndt-4-1073]).

The trophic factor withdrawal syndrome (TFWS) in the etiopathogenesis of human neurodegenerative diseases (HNDDs)
=================================================================================================================

Large scale apoptosis induced by trophic hormone withdrawal was first reported in hormone-dependant tumors ([@b67-ndt-4-1073]). Microenvironmental depletion or functional inability of a wide array of growth factors whose stimulus is necessary for cell survival, such as insulin-like growth factor-1 (IGF-1), PDGF, VEGF, EGF, FGF, and neurotrophins like NGF or others ([@b13-ndt-4-1073];Desmuck et al 1997; [@b50-ndt-4-1073];Counts et al 2000; [@b38-ndt-4-1073]; [@b96-ndt-4-1073]; [@b27-ndt-4-1073]), apart from cytokines like interleukin-2 (IL-2), IL-3, IL-7 ([@b68-ndt-4-1073]), a downregulated Bcl-2 ([@b119-ndt-4-1073]), or an upregulated p53, etc., is sufficient to induce massive neural cell apoptosis ([@b102-ndt-4-1073]; [@b134-ndt-4-1073]) ([Table 3](#t3-ndt-4-1073){ref-type="table"}). In the central nervous system (CNS), a functional deficiency of certain growth factors in the microenvironment can be secondary to: A) a systemic failure of growth factor production, this is, lack of availability; B) inadequate activity of certain trophic molecules in the cell membranes of target tissues of neural origin; C) transmembrane receptor down-regulation or binding deficiency, and/or D) abnormalities in the intracellular signaling cascade. An altered function of any of these circumstances may have a key etiopathogenic role in the pathological cell death of different HNDDs ([@b95-ndt-4-1073]; [@b133-ndt-4-1073]; [@b9-ndt-4-1073]; [@b25-ndt-4-1073]; [@b101-ndt-4-1073]). Apoptotic or parapototic cell suicide can be initiated by removal of different growth factors, while trophic factor withdrawal is a key factor in inducing an apparently *sine qua non* intracellular acidification that seems necessary in mediating the different cell death programs in both neural cells and cancer cells alike ([@b19-ndt-4-1073]; [@b142-ndt-4-1073]). Thus, the systematic clinical utilization of different GFs, alone or in combination, opens new possibilities in the prevention and treatment of HNDDs ([@b18-ndt-4-1073]). This review is an exercise in both translational and transversal research between neurology, hematology, and oncology research in order to propose new pathways towards a better understanding of the pathogenesis of HNDDs to discover new therapeutic approaches through the clinical utilization of GFs and other similar measures in both the prevention and treatment of these processes.

Mediating mechanisms in the pathogenesis of HNDDs. The universal role of Na^+^/H^+^ exchange and intracellular pH in the action of growth and trophic factors. Cellular Darwinism and the law of specificity and nonspecificity in biology
==========================================================================================================================================================================================================================================

The role of Na^+^/H^+^ exchange and intracellular pH as universal mediators and in the activation and inhibition of growth and trophic factors in HNNDs and cancer
------------------------------------------------------------------------------------------------------------------------------------------------------------------

Some of the main areas of cancer research, from etiopathogenesis to treatment at both the basic and clinical levels (malignant transformation, growth and proliferation, cell migration, angiogenesis, the metastatic process, multiple drug resistance to chemotherapy (MDR), oncogene expression, growth factor activity, tumor glycolysis, cell cycling, DNA synthesis, apoptosis, etc.), have been recently integrated under an Unitarian perspective based upon the dynamics of the hydrogen ion and Na^+^/H^+^ antiporter ([@b58-ndt-4-1073]). Similar aspects of cancer have lead some researchers to consider that "cancer Achilles's heel" can hide within the frame of H^+^ dynamics and its secondary effects on cellular metabolism (J. Poúyssegür, personal communication). Furthermore, the most active proton pump inhibitors (PPI) of the amiloride series and beyond, increasingly appear as cancer "magic bullet" because their selective potential to induce a selective metabolic collapse and cell death, apoptosis-mediated or otherwise, of cancer cells and tissues irrespective of origin and cell lineage ([@b110-ndt-4-1073]; [@b137-ndt-4-1073]; [@b65-ndt-4-1073]; [@b58-ndt-4-1073]; [@b97-ndt-4-1073]).

While human and trophic growth factors have different origins and specific target cells, their mediating mechanisms of action at the level of the cell membrane and intracellular signaling show common final pathways in all kinds of cells ([@b60-ndt-4-1073]). First, pro- and antiapoptotic intracellular signaling pathways are already known to a considerable extent, and maps of those intracellular pathways as possible therapeutic targets in different pathologies are already available ([@b52-ndt-4-1073]; [@b104-ndt-4-1073]; [@b73-ndt-4-1073]). Secondly, we have learned from experimental and translational oncology research that a key feature mediating the molecular mechanisms of action in the stimulation by the majority of, if not all, growth factors, is an increase in the rate of exchange of Na^+^ and H^+^. An over-expressed extrusion of H^+^ ions, which is mainly mediated by the membrane-bound Na^+^-H^+^ exchanger, induces an intracellular (IC) alkalinization and the disruption of both the IC--extracellular (EC) homeostasis of the cell ([@b19-ndt-4-1073]; [@b86-ndt-4-1073]; [@b56-ndt-4-1073], [@b58-ndt-4-1073]; [@b106-ndt-4-1073], [@b107-ndt-4-1073]; [@b68-ndt-4-1073];Harguindey 2003; [@b87-ndt-4-1073]; [@b23-ndt-4-1073]; [@b36-ndt-4-1073]). This phenomenon is recognized as a key and specific feature not only in malignant cell transformation but also in the growth and invasion of cancer cells of all lineages and origins, as well as in the activation the metastatic process, through the creation of an abnormal IC--EC proton gradient (the so called "H^+^-gradient reversal") ([@b14-ndt-4-1073]; [@b106-ndt-4-1073]; [@b68-ndt-4-1073]; [@b23-ndt-4-1073]; [@b58-ndt-4-1073]; [@b97-ndt-4-1073]).

The NHE, mainly the NHE-1 isoform, plays an essential and pivotal role in the IC signal transduction pathways of a multiplicity of different hormones, membrane signals, as well as trophic and growth factors (for a review, see [@b58-ndt-4-1073]). The stimulation of this *final common pathway* by all the different kinds of mitogenic factors results in the activation of the Na^+^/H^+^ antiporter and its secondary induction of an elevation of intracellular pH ([@b19-ndt-4-1073]; [@b35-ndt-4-1073]; [@b23-ndt-4-1073]; [@b58-ndt-4-1073]). This phenomenon has been known for some time to represent an early and essential step in mediating cell proliferation and DNA synthesis ([@b19-ndt-4-1073]; [@b86-ndt-4-1073]; [@b72-ndt-4-1073]; [@b49-ndt-4-1073]; [@b56-ndt-4-1073]; [@b106-ndt-4-1073]). Indeed, trophic and growth factors with clear-cut antiapoptotic activity always stimulate the NHE-1 and increase pH~i~, this being a fundamental homeostatic mechanism that protects cells against a pathological fall in pH~i~ ([@b19-ndt-4-1073]; [@b36-ndt-4-1073]; [@b59-ndt-4-1073]). In this way, cell death programs, either through apoptosis and/or parallel mechanisms, can be counteracted ([Table 4](#t4-ndt-4-1073){ref-type="table"}) ([@b110-ndt-4-1073]; [@b68-ndt-4-1073]; [@b107-ndt-4-1073]; [@b58-ndt-4-1073]). Among these antiapoptotic--antiacidification factors are the Bcl-2 family, Bax deletion, certain oncogenes, a dysfunctional p53 suppressor gene, etc. ([@b34-ndt-4-1073]; [@b79-ndt-4-1073];Thangaraju et al 2001). The main bulk of available literature points to the conclusion that cellular neuroprotection is also mediated by a pH~i~-sustaining effect on IC metabolism and homeostasis of an acid-base nature (therapeutic antiapoptosis) ([@b142-ndt-4-1073]), in a similar manner that the survival mechanisms described for cancer antiapoptosis, mainly in multiple drug resistance to chemotherapy (MDR) (pathological antiapoptosis) ([@b51-ndt-4-1073]; [@b115-ndt-4-1073]; [@b48-ndt-4-1073]; [@b142-ndt-4-1073];Simon 2000; [@b58-ndt-4-1073]). Most significantly, in trophic under-stimulation and/or in growth factor deprivation the cell signals to detect IC acidification appear to be the same ones as for spontaneous apoptosis ([@b51-ndt-4-1073]; [@b115-ndt-4-1073]; [@b48-ndt-4-1073]; [@b46-ndt-4-1073]; [@b42-ndt-4-1073]; [@b93-ndt-4-1073]; [@b135-ndt-4-1073]; [@b14-ndt-4-1073]; [@b81-ndt-4-1073]; [@b110-ndt-4-1073]; [@b35-ndt-4-1073]; [@b79-ndt-4-1073]; [@b121-ndt-4-1073]; [@b71-ndt-4-1073]; [@b36-ndt-4-1073]) ([Figure 1](#f1-ndt-4-1073){ref-type="fig"}). In this line, antiapoptotic Bcl-2 or a deleted pro-apoptotic Bax protein have been shown to directly prevent cellular acidification and thus, cellular injury ([@b93-ndt-4-1073]; [@b135-ndt-4-1073]; [@b14-ndt-4-1073]; [@b17-ndt-4-1073]; [@b129-ndt-4-1073]). This IC homeostatic acid-base approach opens new possibilities in the strategy to implement new preventive and/or therapeutic measures in HNDDs, hitting as a key and pivotal therapeutic target pH~i~ homeostasis with any drug or biological compound that, alone or in combination (imidazole, chloroquine, neurotrophic or other growth factors, Bcl-2, cytokines, oncogenes, cell proteins, gene products, platelet transfusions) that activate the NHE-1 and/or decrease nitric oxide (NO) production, thus sustaining pH~i~ within normal limits and allowing IC proton homeostasis and cell function as a whole to be kept within a physiological range ([Table 3](#t3-ndt-4-1073){ref-type="table"}).

Parallel processes of the pathological apoptosis in HNDDs and the overcoming of the resistance to apoptosis (pathological antiapoptosis) in cancer therapeutics
---------------------------------------------------------------------------------------------------------------------------------------------------------------

What spontaneously takes place in HNDDs (pathological apoptosis) ([@b100-ndt-4-1073]), is the same phenomenon that cancer therapeutics attempt to selectively induce through a wide array of different approaches and methods (therapeutic apoptosis) ([Figure 1](#f1-ndt-4-1073){ref-type="fig"}). Similarly, it has been shown that one of the main mechanisms by which cancer cells are resistant to chemotherapeutic treatment (MDR) is secondary to the fact that most cancer cells posses concerted defensive mechanisms that allow them to maintain their intracellular acid-base situation well above normal levels through all kinds of damaging microenvironmental circumstances. This has been called "*the neostrategy of cancer cells and tissues*" ([@b58-ndt-4-1073]). Otherwise, a successful treatment in cancer is mediated by the activation of a low pH~i~-mediated apoptotic chain reaction cascade ending in cancer cell death (therapeutic apoptosis) ([@b42-ndt-4-1073]; [@b93-ndt-4-1073]; [@b150-ndt-4-1073]; [@b58-ndt-4-1073]; [@b36-ndt-4-1073]; [@b75-ndt-4-1073]). Some of these mechanisms are mediated by executionary caspases or by the therapeutic activation of a JNK apoptotic pathway in cases of successful chemotherapy ([@b94-ndt-4-1073]). Most interestingly, a parallel phenomenon, namely, an oxidative stress-mediated activation of the c-Jun -N-terminal kinase, takes place in AD (see [Figure 1](#f1-ndt-4-1073){ref-type="fig"}). Furthermore, JNK activation is also mediated by directly inducing a low pH~i~ and by amiloride treatment (Lachapelle et al 2007). Other mechanisms of successful cancer treatment include overcoming blockades to cancer cell apoptosis by inhibiting the Bcl-2 antiapoptotic family, whose activity is not surprising that is mediated by IC alkalinization and inhibited by cell acidification ([@b109-ndt-4-1073]; [@b153-ndt-4-1073]; [@b64-ndt-4-1073];Shimuzu et al 1998; [@b155-ndt-4-1073];Zhiuza et al 1998; [@b135-ndt-4-1073]; [@b81-ndt-4-1073]; [@b131-ndt-4-1073]; [@b145-ndt-4-1073]). Resistance to chemotherapy (MDR) can also be achieved by similar pH-related methods ([@b116-ndt-4-1073]; [@b58-ndt-4-1073]). A large deal of accumulated data in this area indicates that the study of Bcl-2 as an antiapototic agent seems secondary to an alkalinizing pH~i~ effect, another feature that can be integrated within the H^+^-mediated model ([@b109-ndt-4-1073]; [@b135-ndt-4-1073]; [@b81-ndt-4-1073]). This makes it highly surprising that even the more recent reviews on cell death mechanisms and resistance to them, either in cancer and HNDDs, either completely ignore the dynamics of the hydrogen ion in these situations or they are granted a meaningless secondary role at the most ([@b100-ndt-4-1073]; [@b147-ndt-4-1073]; [@b104-ndt-4-1073]; [@b128-ndt-4-1073]). Even more, malignant cell apoptosis can be *selectively* induced by proton pump inhibitors (PPI) like HMA (5-(N, N-hexamethylene)-amiloride) ([@b110-ndt-4-1073]), or acid-mediated stimulation of p53 ([@b150-ndt-4-1073]) ([Table 4](#t4-ndt-4-1073){ref-type="table"} and [Figure 1](#f1-ndt-4-1073){ref-type="fig"}).

Multiple drug resistance to different chemotherapeutic agents (MDR) can be overcome by HMA or other PPI of the amiloride series, another low pH~i~-mediated phenomena ([@b116-ndt-4-1073]; [@b58-ndt-4-1073]; [@b85-ndt-4-1073], [@b36-ndt-4-1073]). In summary, all the available evidence indicates that the more reductionistic and fragmented model represented by the detailed study of any individual factors as well as the intricate abnormalities of the intracellular signaling pathways can be inserted within a more comprehensive and integral homeostatic paradigm of an acid-base nature as represented by the IC--EC dynamics of the hydrogen ion (H^+^). This acquires further significance when attention is paid to the fact that the dynamics of proton movements in and out of the cell and its transmembrane gradients seem to be the ultimately responsible factor and mechanism for the apoptosis-antiapoptosis machinery in both HNDDs and cancer ([@b48-ndt-4-1073]; [@b46-ndt-4-1073]; [@b42-ndt-4-1073]; [@b93-ndt-4-1073]; [@b142-ndt-4-1073]; [@b150-ndt-4-1073]; [@b57-ndt-4-1073], [@b58-ndt-4-1073], [@b59-ndt-4-1073]; [@b81-ndt-4-1073]; [@b100-ndt-4-1073]; [@b129-ndt-4-1073]; [@b147-ndt-4-1073]; [@b71-ndt-4-1073]; [@b104-ndt-4-1073]; [@b75-ndt-4-1073]).

In spite that cancer cells seem able to evade apoptosis by trophic factor deprivation in many cases ([@b132-ndt-4-1073]; [@b136-ndt-4-1073]), antihormonal and antigrowth factors are being tried in different therapeutic attempts in the oncology setting (Shegal et al 1994; [@b130-ndt-4-1073]). These and other parallel considerations relating H^+^ dynamics and GF activity allow to place the biochemistry and molecular biology of HNDDs and cancer at both ends of an apoptotic-antiapoptotic metabolic spectrum ([@b55-ndt-4-1073], [@b59-ndt-4-1073]) ([Tables 3](#t3-ndt-4-1073){ref-type="table"} and [4](#t4-ndt-4-1073){ref-type="table"}). The same unitarian perspective that has made possible to integrate the main areas of basic and clinical oncology research ([@b53-ndt-4-1073]; [@b56-ndt-4-1073], [@b58-ndt-4-1073]), now allows to advance another new concept: that what is pathological and damaging for some diseases (the spontaneous apoptosis of HNDDs) can be therapeutic and beneficial for their metabolic and homeostatic opposites (the antiapoptosis of malignancy) ([Table 4](#t4-ndt-4-1073){ref-type="table"}). Thus, a primordial approach to IC homeostasis may open new and untrodden ways towards entirely new therapeutic approaches, aiming at the Na^+^/H^+^ antiporter, other membrane proton pumps and NO production and control as primordial therapeutic targets, either in the induction of selective low pH-mediated apoptosis in cancer treatment through the utilization of proton transport inhibitors (therapeutic apoptosis) or, in the opposite direction, counteracting IC acidification in HNDDs (therapeutic antiapoptosis) ([@b138-ndt-4-1073]; [@b110-ndt-4-1073]; [@b137-ndt-4-1073]; [@b65-ndt-4-1073]; [@b58-ndt-4-1073];Poüysségur et al 2007).

Terminal pathogenesis of apoptotic or para-apoptotic cell death in HNDDs. NO, oxidative stress, and cellular pH~i~
------------------------------------------------------------------------------------------------------------------

When deprived of trophic factors (TFWS), motor neurons undergo a programmed cell death program, apparently through nitric oxide-dependent apoptosis ([@b62-ndt-4-1073]; [@b142-ndt-4-1073]; [@b39-ndt-4-1073]; [@b149-ndt-4-1073]; [@b40-ndt-4-1073]), and/or superoxide production ([@b77-ndt-4-1073]) and/or caspase activation ([@b138-ndt-4-1073]; [@b83-ndt-4-1073]; [@b28-ndt-4-1073]; [@b33-ndt-4-1073]; [@b29-ndt-4-1073]). The induction of NO-related mechanisms share a common final pathway that involves nitric oxide synthase (NOS) and peroxynitrite formation. NO has been linked, partly because to its oxidative role, to the development of several neurodegenerative disorders, seemingly by activating a pHi-related apoptotic cascade ([@b25-ndt-4-1073]). Furthermore, the formation of NO by astrocytes has been suggested to contribute to the neurodegenerative process, while NO production is significantly elevated in platelets from AD patients ([@b45-ndt-4-1073]). This very same mechanism proves to be of value in inducing apoptosis, via necrosis, in neoplastic cells ([@b113-ndt-4-1073]) ([Table 3](#t3-ndt-4-1073){ref-type="table"}).

The seminal work of [@b142-ndt-4-1073] in neurons has shown that lowering pH~i~ from 7.36 to 7.09/7.00 through exposure to NO sets in motion a programmed cell death (PCDP) program, increasing DNA fragmentation and decreasing neuronal survival (low pH~i~-mediated metabolic collapse). This phenomenon is induced by the activation of three low pH~i~-dependent endonucleases responsible for neuronal injury ([Figure 1](#f1-ndt-4-1073){ref-type="fig"}). Furthermore, the formation of pH~i~-lowering pro-apoptotic NO by astrocytes suggests a potential for NO inhibitors in the treatment of this disease, most likely through the stabilization of IC acid-base homeostasis and the prevention of a deadly drop in pH~i~ (Harguindey et al 2003; [@b12-ndt-4-1073]) ([Figure 1](#f1-ndt-4-1073){ref-type="fig"}). Other compounds with different anti-NO properties like superoxide dismutase, minocycline, NGF, etc, have also shown neuroprotective effects ([@b69-ndt-4-1073]; [@b149-ndt-4-1073]; [@b40-ndt-4-1073]). The stimulation of oxidative stress by NO has been involved in the pathogenesis of dementia ([@b25-ndt-4-1073]), while oxidative stress and/or reactive oxygen species (ROS) have been widely considered as a key factor in neuronal degradation ([@b59-ndt-4-1073]). Superoxide (SO) formation induced by growth factor deprivation induces apoptosis ([@b77-ndt-4-1073]). This phenomenon is further increased after reacting SO with NO to form peroxynitrite ([@b40-ndt-4-1073]). In contrast, low or physiological concentrations of NO prevents apoptosis ([@b29-ndt-4-1073]). In summary, the dynamics of the killing mechanism (see also [Figure 1](#f1-ndt-4-1073){ref-type="fig"}), are:
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The study of the molecular biology of cancer cells has shown that the inhibition of the electroneutral membrane exchanger NHE-1 induces intracellular acidification by entrapping hydrogen ions within the cell ([@b76-ndt-4-1073]; [@b102-ndt-4-1073];Harguindey et al 2003). A severe intracellular acidosis below a certain threshold (pH~i~:±6.8) is an essential factor in setting up a cascade-like chain reaction ending up in the metabolic collapse preceding apoptosis, either in cancer cells (therapeutic apoptosis) ([@b110-ndt-4-1073], [@b36-ndt-4-1073]) or in dying cells of neural origin (pathological or degenerative apoptosis) ([Figure 1](#f1-ndt-4-1073){ref-type="fig"}) ([@b51-ndt-4-1073]; [@b115-ndt-4-1073]; [@b48-ndt-4-1073]; [@b56-ndt-4-1073]; [@b76-ndt-4-1073]; [@b102-ndt-4-1073]; [@b93-ndt-4-1073], [@b88-ndt-4-1073]; [@b142-ndt-4-1073]; [@b135-ndt-4-1073]; [@b81-ndt-4-1073]; [@b110-ndt-4-1073]; [@b35-ndt-4-1073]; [@b121-ndt-4-1073]; [@b144-ndt-4-1073]; [@b71-ndt-4-1073]).

Cellular Darwinism. The law of specificity and nonspecificity in biology
------------------------------------------------------------------------

From the point of view of biological evolution, the simplest way (and to follow Darwinian rules nature always chooses the simplest possible way in order to solve its biological problems and preserve the stability and continuation of life) is that a wide array of trophic, growth factors and hormones have different kinds of target cells with specific receptors for different cell lineages. This represents a *qualitative* and *specific* variation. At the same time, cellular physiology has a very small number of transduction mechanisms from the membrane to the interior of the cell to influence intra-cellular signaling pathways that are shared by all kinds of cells. These mechanisms may only vary from one another in some *quantitative*, *nonspecific aspects*. The procedure of choosing the kind of response is through a selective, however variable distribution of specific receptors in the different cell lineages concerted with a few number of membrane-bound signals, as the family of the proton pump transporting systems, and from there on to mostly shared IC signaling pathways. This is the simplest possible way that can be imagined. Much more difficult would be that nature would have chosen that all cells would have the same or similar receptors. Should this have been the case, all cells would be equally sensitive to all different kinds of stimulating or inhibiting hormones and growth factors in order to induce numberless and different effects in each cell or cell lineage. In this case it would have been necessary to select the kind of response through a great number and diversity of signals and/or intracellular transduction mechanisms in the different cells and/or lineages. This complication is so great that it rules itself out. It is much more logical that evolution selects target cells providing them with specific receptors, which are the mediating mechanisms responsible for selecting the kind cellular response, than to have numberless IC signaling factors and pathways for each lineage or cell ([@b84-ndt-4-1073]; [@b60-ndt-4-1073]). In this way, a countless diversification of effects is reduced to the qualitative and quantitative distribution of membrane receptors, which would decrease the information and stimulus-response systems of cells to the smallest number and the least possible degree of complication. All the above-mentioned features can be represented through the following scheme:
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The fact that all the different kinds of cells of living organisms and a multiplicity of mitogenic stimuli, hormones and growth factors share the same universal transport systems, mainly the Na^+^/H^+^ antiporter but also a few other membrane-bound proton pumps at the cell membrane ([@b58-ndt-4-1073]), allows to formulate *a law that unifies and combines specificity and nonspecificity in biology*. Similar examples of this law at the level of intermediary metabolism, are:

a.  Glucose transporters sensitive to insulin (GLUT 4), that are only present in fat, muscle, and heart tissues.

b.  Adrenalin receptors for the stimulation of glucogenolysis, that are only present in muscle and liver.

c.  Glucagon receptors for glucogenolysis, only present in liver.

In all these cases, the mechanism of intracellular stimulation is always the same one: activation of adenylate cyclase to produce cAMP) ([@b84-ndt-4-1073]). If we apply this law to neuronal neuroprotection, any trophic factors with a clear-cut antiapoptotic activity also stimulate the NHE-1 exchanger ([@b86-ndt-4-1073]; [@b72-ndt-4-1073]). Among the different membrane-bound proton pumps, the NHE1 appears to be the main homeostatic mechanism that protects cells against a pathological decrease in pH~i~ and so, against cell death through cytosolic acidification. Thus, in many cases cellular protection seems to be ultimately mediated by a pH~i~-sustaining effect responsible for a physiological equilibrium and intracellular homeostasis of an acid-base nature. We have called this phenomena "therapeutic antiapoptosis", a parallel concept to the "pathological antiapoptosis" which is characteristic to cancer cells, mainly in cases of multiple drug resistance to antichemotherapuetic agents (MDR) (Roepe et al 2003; [@b60-ndt-4-1073]) ([Table 4](#t4-ndt-4-1073){ref-type="table"}). In summary, a primordial approach to the dynamics of cellular proton homeostasis gives way to new therapeutic possibilities, strategies and targets both in the treatment of HNDDs and neoplastic diseases ([@b110-ndt-4-1073]; [@b58-ndt-4-1073], [@b59-ndt-4-1073]).

The pH~i~ factor and platelet abnormalities in AD. Therapeutic possibilities of human growth factors in the treatment of the trophic factor withdrawal syndrome in HNDDs
========================================================================================================================================================================

Intracellular homeostasis. The pH~i~ factor
-------------------------------------------

The final common pathway mediating cellular responses to different mitogenic stimulus, growth factors and other membrane signals such as hormones, has been repeatedly recognized to be secondary to the induction of an elevation of pH~i~ ([@b19-ndt-4-1073]; [@b86-ndt-4-1073]; [@b72-ndt-4-1073]; [@b56-ndt-4-1073]; [@b23-ndt-4-1073]). Contrariwise, apoptosis, either in HNDDs or other settings, is largely mediated by IC acidification ([@b142-ndt-4-1073]; [@b58-ndt-4-1073]). Contrariwise, maintaining IC alkaline levels at the level of pH~i~ =7.60 prevents neuronal injury, not only implying pH~i~ as a critical factor in PCD but also indicating a possible role for therapeutic cellular alkalinization in the prevention and treatment of neuronal degeneration, as shown by [@b142-ndt-4-1073]. These authors and others ([@b59-ndt-4-1073]) have concluded that counteracting a drop in pH~i~ through trophic and/or peptide growth factors is a most attractive therapeutic target against neuronal degeneration and pathological death. Furthermore, inhibiting NO production by NO inhibitors, like mefenamic acid and thiadiazolidinones, and so IC acidification, has been correctly proposed as a therapeutic option in the treatment of AD ([@b142-ndt-4-1073]; [@b12-ndt-4-1073]; [@b59-ndt-4-1073]). Thus, beyond multiple etiological causes and early EC factors that can be involved, a universal mechanism of an acid-base nature appears to be the pivotal and key event in downregulating caspase-mediated or caspase-independent IC signaling pathways leading in many cases to cell death in HNDDs and, similarly, in different lineages of cancer cells ([@b51-ndt-4-1073]; [@b76-ndt-4-1073]; [@b89-ndt-4-1073]; [@b102-ndt-4-1073]; [@b48-ndt-4-1073]; [@b109-ndt-4-1073]; [@b46-ndt-4-1073]; [@b62-ndt-4-1073]; [@b93-ndt-4-1073], [@b88-ndt-4-1073]; [@b142-ndt-4-1073]; [@b135-ndt-4-1073]; [@b150-ndt-4-1073]; [@b78-ndt-4-1073]; [@b81-ndt-4-1073]; [@b110-ndt-4-1073]; [@b63-ndt-4-1073]; [@b79-ndt-4-1073]; [@b105-ndt-4-1073]; [@b107-ndt-4-1073]; [@b71-ndt-4-1073]; [@b112-ndt-4-1073];Vaghefiet al 2004; [@b73-ndt-4-1073]; [@b16-ndt-4-1073], [@b36-ndt-4-1073]) ([Figure 1](#f1-ndt-4-1073){ref-type="fig"}). In summary, any therapeutic effort to keep IC acid-base homeostasis within normal or higher than normal levels, is likely to be of significant benefit in the prevention and treatment of HNDDs.

Platelet abnormalities in AD: Interdisciplinary hematology to neurology transversal research
--------------------------------------------------------------------------------------------

Evidence for a role of platelet dysfunction, structural to functional, in AD patients arises from different studies ([@b159-ndt-4-1073], [@b160-ndt-4-1073]). [@b12-ndt-4-1073] and [@b25-ndt-4-1073] have reported that abnormal platelet function related to an increase in NO-producing systems play an important role in the pathogenesis of AD and in neuronal degeneration. From the structural side, the presence of abnormal coated-platelets with the capacity to retain amyloid precursor protein in their surface has been shown in early stage AD and MCI (mild cognitive impairment), a feature that also shows a significant relationship with disease progression ([@b98-ndt-4-1073]). Such abnormalities directly relate platelet abnormalities with the pathogenesis of at least some HNDDs, while at the same time they suggest that the supply of healthy exogenous platelets with high contents of PDGF and other platelet-derived GFs may have a significant therapeutic effect in at least certain HNDDs like AD ([Figure 1](#f1-ndt-4-1073){ref-type="fig"} and [Table 2](#t2-ndt-4-1073){ref-type="table"}).

Growth factors in neuronal protection
-------------------------------------

If one of the main trophic factors that stimulate growth and metabolism of muscle cells is plain exercise, the nervous system is stimulated by certain GFs, neurotrophic, platelet-derived, and beyond. The lack of cell trophism in different degenerative diseases makes it highly advisable to undertake clinical studies to detect the presence, decrease or even absence of either systemic, microenvironmental and/or cellular growth factors and other antiapoptotic substances (PDGF, VEGF, NGF, tyrosine kinases, Bcl-2, Bcl-X, etc.), not only in HNDDs but also in other systemic and nonneural degenerative diseases ([Table 1](#t1-ndt-4-1073){ref-type="table"}) ([@b111-ndt-4-1073]; [@b147-ndt-4-1073]; [@b146-ndt-4-1073]; [@b3-ndt-4-1073], [@b4-ndt-4-1073], [@b5-ndt-4-1073], [@b6-ndt-4-1073], [@b7-ndt-4-1073], [@b8-ndt-4-1073]; [@b148-ndt-4-1073]; [@b43-ndt-4-1073]). Ultrastructural-morphological studies and determinations of the content and activity of α-granules in platelets of patients with HNDDs, as well as measuring the concentration of the different PDGFs in the platelets of patients with AD and other HNDDs represent an unexplored field of research that may lead to improving the understanding of the pathogenesis of HNDDs ([@b123-ndt-4-1073]). In order to do this, the technology necessary to perform these measurements is now available ([@b5-ndt-4-1073], [@b6-ndt-4-1073]).

Among the different PDGF, recent evidence points to a pivotal role for VEGF in neuronal protection ([@b66-ndt-4-1073]; [@b22-ndt-4-1073]; [@b126-ndt-4-1073], [@b127-ndt-4-1073]; [@b123-ndt-4-1073]). Decreased VEGF activity has been shown in different HNDDs. Recently, serum VEGF levels of patients with AD were compared with control subjects ([@b80-ndt-4-1073]). The mean concentration of VEGF in the patient group was significantly lower than in the controls. These authors concluded that a decrease in serum levels of VEGF could contribute to the neurodegenerative process in AD. While no differences in serum VEGF levels between AD patients and controls have been found in other studies, low VEGF activity has also been reported in patients with ALS ([@b31-ndt-4-1073]). The VEGF deficiency trophic effect can be related to a decrease of VEGF secretion from coated-platelets secondary to already described abnormalities related to the retention of APP protein on their surface ([@b12-ndt-4-1073]; [@b98-ndt-4-1073]). Other authors have found co-accumulation of VEGF with β-amyloid in AD, as well as a strong binding of VEGF to it, suggesting that secondary VEGF deficiency under hypoperfusion may contribute to neurodegeneration and vascular dysfunction in the progression of AD ([@b31-ndt-4-1073]).

A decreased secretion and release of VEGF in the supernatants of circulating natural killer (NK) immune cells in patients with AD compared to normal controls and patients with other types of senile dementias has also been reported. This down-regulation of VEGF production has been demonstrated in peripheral immune cells of patients suffering from AD ([@b123-ndt-4-1073]). These findings become even more significant when the pivotal importance of VEGF in brain angiogenesis, neuroprotection, and cerebrovascular exchange of nutrients is considered ([@b157-ndt-4-1073]; [@b126-ndt-4-1073]; [@b152-ndt-4-1073]; [@b31-ndt-4-1073]; [@b123-ndt-4-1073]) From a therapeutic point of view, direct application of VEGF delays the onset of paralysis, improves motor function and increases survival in a rat model of AD ([@b127-ndt-4-1073]; [@b141-ndt-4-1073]). Since the highest known accumulation of VEGF can be found in platelets and leukocytes ([@b70-ndt-4-1073]), cyclic transfusions of healthy young platelets and, perhaps, leukocytes too, may represent the easiest and most natural available source of VEGF and other trophic growth factors and a significant new therapeutic approach to certain HNDDs ([@b59-ndt-4-1073]).

Similarly, mice lacking epidermal growth factor receptor (EGFR) develop neurodegeneration through Akt-caspase dependent apoptosis of the frontal cortex ([@b143-ndt-4-1073]), this representing a further example of neuronal degeneration as part of the trophic factor withdrawal syndrome (TFWS). Finally, the emerging role of other GFs, like FGF, mainly through its interaction with its receptors, has been reported to present a significant role in brain neuronal trophism, repair and protection, and may also play a role in the treatment of certain mental disorders ([@b114-ndt-4-1073]).

The therapeutic potential of different neurotrophic factors in HNDDs has been studied for more than two decades (Hefty et al 1983; Varon et al 1987; [@b134-ndt-4-1073], [@b26-ndt-4-1073]). [@b13-ndt-4-1073] initially showed that different neurotrophins induce growth and proliferation of cells of neural origin. The inhibition of NGF has been considered to be involved in the pathogenesis and treatment of the prodromal stages of AD ([@b134-ndt-4-1073]; [@b26-ndt-4-1073], [@b118-ndt-4-1073]). However, more recent clinical trials using NGF have failed to show significant results. Besides, the intracerebral local application of NGF faces many technical problems ([@b17-ndt-4-1073]; [@b37-ndt-4-1073]; [@b30-ndt-4-1073]). However, when glial cell line neurotrophic factor (GDNF) is infused via encapsulated cells in animal models of PD some positive results are obtained (Sajadi et al 2005). Furthermore, it has been reported that the local application of NGF into the putamen has produced sustained benefits in a small series of patients with PD ([@b122-ndt-4-1073]). Other neurotrophic factors like pigment epithelium-derived factor (PEGF) protects retinal ganglion cells ([@b92-ndt-4-1073]). Gene transfer factors and antiapoptotic promoting factors like Bcl-2 or other GFs have also been tried ([@b30-ndt-4-1073]; [@b124-ndt-4-1073]). Finally, hormones like thyrotrophin-releasing hormone (TRH) and its derivatives, as well as testosterone or estrogens, also play the role of GFs in protecting cells from neural injury in a similar manner than certain antioxidants like N-acetylcysteine ([@b151-ndt-4-1073]; [@b15-ndt-4-1073]: [@b41-ndt-4-1073]). GFs besides VEGF and EGF, like IGF-1, whose deficiency has also been related to the pathogenesis of AD ([@b9-ndt-4-1073]), are able to promote neural survival and differentiation ([@b95-ndt-4-1073]). Finally, different antiapoptotic therapies for neurodegenerative diseases based upon the application of exogenous products that stimulate cell trophism, such as propargylamines, alpha-2-adrenergic receptor activators, minocycline, etc, are at the present time in preclinical stages of research ([@b133-ndt-4-1073], [@b134-ndt-4-1073]; [@b73-ndt-4-1073]).

Use of PDGFs in clinical medicine and potential utilization of platelet transfusions in the treatment of HNDDs
==============================================================================================================

One possibility of counteracting programmed cell death programs (PCDP) driven by deprivation of trophic and/or growth factors, would be to study the therapeutic potential of PDGF in HNDDs, as it has been recently tried in nonneural pathology ([@b73-ndt-4-1073]; [@b6-ndt-4-1073]; [@b101-ndt-4-1073]) ([Table 1](#t1-ndt-4-1073){ref-type="table"}). Neurons, glial cells, and the pigmentary epithelial cells of the retina all contain platelet-derived growth factor receptors (PDGFR), making them classic therapeutic targets for PDGF. The cyclic administration of PDGFs in HNDDs through the exogenous supply of healthy platelets should be considered in a similar way that a wide variety of human pathologies are nowadays successfully treated through loco-regional application of autologous platelet releseates obtained by simple clinical procedures ([@b44-ndt-4-1073]; [@b2-ndt-4-1073]). This new research field allows for important and exciting new perspectives in opening untrodden areas of research and treatment of degenerative diseases, either from neural origin or otherwise, where a lack of one or more trophic factors is involved in their pathogenesis, including any kind of degenerative pathology where stimulation of new tissue growth or regrowth is necessary. Nowadays, clot preparations containing high concentrations of PDGF and metabolites that stimulate cell trophism, growth and proliferation, are being used with increasing frequency in a wide range of medical and surgical contexts apart from neurology, from dentistry and oral implantology to orthopaedics, gastric and skin ulcer treatment, eye disorders, etc, successfully inducing new tissue formation and accelerated tissue repair in different tissues and locations ([@b2-ndt-4-1073]). [Table 1](#t1-ndt-4-1073){ref-type="table"} summarizes some of the therapeutic applications of platelet-based technology in modern clinical medicine. These platelet-releseates contain high concentrations of a wide array of mitogenic and pro-angiogenic factors, mainly platelet-derived growth factor PDGF, TGF-β1, EGF, VEGF, PDEGF, IGF-1, and HGF, as well as cytokines PF4 and CD40L, apart from lower concentrations of other factors like β-FGF ([@b6-ndt-4-1073]). Some of these factors show a potent stimulating effect on cell growth, proliferation and viability, to a large extent because of their positive effects on angiogenesis. The possibility of translating these successful clinical results to the prevention and treatment of HNDDs is one of the main medical challenges for the next few years.

Conclusions
===========

The main conclusions of this study are:

a.  The exogenous utilization of human growth factors, platelet-derived or otherwise, present a therapeutic potential in the treatment of certain human neurodegenerative diseases (HNDDs).

b.  There is a large deal of both theoretical and experimental evidence, both at basic and clinical levels, to consider the cyclic and systemic use of healthy platelet transfusions in early stages of certain HNDDs like AD.

c.  The therapeutic failure in the prevention and treatment of HNDDs can be secondary to a certain extent to lack of knowledge about the implications of the different trophic factors in the pathogenesis of HNDDs within the frame of the TFWS.

d.  Every effort to maintain intracellular acid-base homeostasis within the physiological range in HNDDs, thus preventing the metabolic collapse induced by cell acidification and its secondary activation of cell death programs, will help to better understand, prevent and treat HNDDs.

e.  In the prevention and treatment of HNDDs, a more effective pharmacological inhibition of the formation of NO by neural cells is needed.

f.  Pathological and spontaneous programmed cell death programs in HNDDs, apoptotic or otherwise, are processes that dwell at opposite ends of an acid-base/homeostatic spectrum when compared with the resistance to the induction of apoptotsis that characterizes malignant cells and tissues (pathological antiapoptosis).
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###### 

Use of platelet-based technology in modern clinical medicine

  Objective                                       Results                                                                                                                                                   References
  ----------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------
  Gastric ulcer healing                           Treatment with platelet-rich plasma significantly accelerated ulcer healing                                                                               [@b148-ndt-4-1073]
  Chronic ulcer treatment                         At 8 weeks, the mean percentage of surface healed in the PRGF group was significantly higher than in the control group (73% versus 21.4%) (*P* \< 0.05)   [@b5-ndt-4-1073]
  Bone regeneration in sinus floor augmentation   Bone densitometric values and bone amount were higher in sites treated with PRP                                                                           [@b24-ndt-4-1073]
  Nerve regeneration                              The best results were obtained when the nerves were sutured and PRP was added to the sutures, showing a neurotrophic effect                               [@b43-ndt-4-1073]
  Repair of chronic elbow tendinosis              At final follow-up (mean 25.6 months), PRP patients reported 93% reduction in pain compared with before the treatment                                     [@b90-ndt-4-1073]
  Repair of anterior cruciate ligament            Collagen-PRP mixture resulted in significant improvements in load at yield, maximum load, and linear stiffness at 4 weeks post-treatment                  [@b91-ndt-4-1073]
  Expansion of mesenchymal stem cells (MSCs)      MSCs maintained their osteogenic, chondrogenic, and adipogenic differentiation properties and their immuno-suppressive activity                           Doucet et al 2005
  Dry eye symptoms                                Symptoms improved significantly in 89% of the 18 patients. Improvement on lachrymal meniscus and conjunctival hyperemia were observed                     [@b1-ndt-4-1073]

**Abbreviations:** PRGF, preparation rich in growth factors; PRP, platelet-rich plasma; MSCs, mesenchymal stem cells. (For further details see [@b6-ndt-4-1073]).

###### 

Growth factors contained in normal platelets

  Growth factors                          Function
  --------------------------------------- ------------------------------------------------
  PDGF, TGF-b1 and-2, EGF, VEGF (A y C)   Chemotaxis, cell proliferation
  bFGF; HGF, BMP-2, -4, -6, CTGF          Cell trophism, coagulation, angiogenesis, etc.

**Abbreviations:** PDGF, platelet-derived growth factors; TGF-b1 and -2, transforming growth factor; EGF, epidermal growth factor; VEGF, vasoendothelial growth factor; bFGF, fibroblastic growth factor; HGF, hepatocyte growth factor; BMP-2, -4, -6, bone morphogenetic protein; CTGF, connective tissue growth factor. (For further details see [@b2-ndt-4-1073]).

###### 

Opposed trends of apoptotic-related parameters and therapeutic directions in human neurodegenerative diseases (HNDDs) and cancer

                               HNDDs (Alzheimer's disease, etc)                                                              Cancer
  ---------------------------- --------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------
  **Factors involved:**                                                                                                      
  Apoptosis                    ↑ (pro-apoptosis, pathological)                                                               ↓ (antiapoptosis, pathological)
  Trophic factors              ↓                                                                                             ↑
  Caspase activity             ↑                                                                                             ↓
  Bax activity                 ↑                                                                                             ↓
  p53 activity                 ↑                                                                                             ↓ (or mutated)
  Bcl-2                        ↓                                                                                             ↑
  Na^+^/H^+^ exchanger         ↓(?)                                                                                          ↑
  pH~i~                        ↓                                                                                             ↑
  Oxidative stress             ↑                                                                                             ↓
  **Therapeutic directions**                                                                                                 
  GFs                          To stimulate (PDGF, VEGF, NGF)                                                                To inhibit (IDN-5370, z-VAD-fmk)
  Caspases                     To inhibit                                                                                    To stimulate
  c-Jun protein kinase         To inhibit                                                                                    To stimulate
  Apoptosis                    To inhibit (antiapoptosis)                                                                    To stimulate (pro-apoptosis)
  Antioxidants                 Indicated                                                                                     Contraindicated (?)
  Na^+^/H^+^ Antiporter        To stimulate (Bcl-2, cloroquine, imidazole, GFs (G-CSF, PDGFs, etc.): Platelet transfusions   To inhibit (amiloride, Il-2, LAK, lovastatin, squalamine, staurosporine, etc.)

**Note:** For further details see [@b59-ndt-4-1073].

###### 

pH~i~, apoptosis and antiapoptosis in HNDDs and cancer

             HNDDs                       Cancer
  ---------- --------------------------- ----------------------------
  **↑pHi**   Therapeutic antiapoptosis   Pathological antiapoptosis
  **↓pHi**   Pathological apoptosis      Therapeutic apoptosis
